Detalhe da pesquisa
1.
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Cell
; 172(4): 857-868.e15, 2018 02 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29336889
2.
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Mol Cancer
; 13: 143, 2014 Jun 05.
Artigo
Inglês
| MEDLINE | ID: mdl-24898067
3.
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Breast Cancer Res Treat
; 141(1): 67-78, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23963659
4.
Author Correction: In-vivo vascular application via ultra-fast bioprinting for future 5D personalised nanomedicine.
Sci Rep
; 10(1): 18004, 2020 Oct 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33077845
5.
In-vivo vascular application via ultra-fast bioprinting for future 5D personalised nanomedicine.
Sci Rep
; 10(1): 3205, 2020 02 21.
Artigo
Inglês
| MEDLINE | ID: mdl-32081937
6.
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.
Oncotarget
; 8(54): 91841-91859, 2017 Nov 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29190880
7.
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system.
Biosens Bioelectron
; 68: 791-797, 2015 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25687585
8.
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
PLoS One
; 10(11): e0141795, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26536031
9.
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Mol Cancer Ther
; 14(8): 1916-27, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26013318
10.
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Cancer Chemother Pharmacol
; 73(2): 299-307, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24258456
11.
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
PLoS One
; 8(10): e78656, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-24167634